Biostage, Inc. entered into securities purchase agreements with certain investors in a private placement an aggregate of 1,000,967 common shares at a price of $6 per share for the gross proceeds of $6.005802 million on March 31, 2023.
Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | +3.11% | -5.69% | -53.51% |
1st Jan change | Capi. | |
---|---|---|
-53.51% | 33.21M | |
+11.76% | 226B | |
+9.76% | 188B | |
+13.76% | 137B | |
+25.95% | 108B | |
+0.53% | 63.19B | |
+13.02% | 52.26B | |
+4.86% | 51B | |
+7.45% | 43.89B | |
+6.35% | 38.07B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Biostage, Inc. announced that it expects to receive $6.005802 million in funding